MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
03 Décembre 2024 - 2:17PM
Business Wire
- Expansion of 2021 clinical supply agreement for Phase 2
clinical trial
- Next stage of trial to further assess efficacy of THIO in third
line non-small cell lung cancer patients
- MAIA expects new patient enrollment to begin soon in the
expansion of THIO-101
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”,
the “Company”), a clinical-stage biopharmaceutical company
developing targeted immunotherapies for cancer, today announced
that it has amended the 2021 clinical supply agreement with
Regeneron for the expansion portion of THIO-101, its Phase 2
clinical trial evaluating THIO in sequential administration with
cemiplimab (Libtayo®). The new expansion will further assess the
efficacy of MAIA’s lead asset, THIO, sequenced with immune
checkpoint inhibitor (CPI) Libtayo® (cemiplimab) for advanced
non-small cell lung cancer (NSCLC) patients receiving third-line
therapy who were resistant to previous checkpoint inhibitor
treatments and chemotherapy.
The original 2021 agreement between MAIA and Regeneron was
designed to supply the original THIO-101 trial through the dose
selection and safety evaluation process. The THIO-101 trial has
been amended and expanded to further evaluate efficacy at the
target dose and target third line patient population.
"In keeping with our clinical strategy for THIO, we look forward
to continuing our collaboration with Regeneron to evaluate THIO’s
anti-tumor activity when followed by PD-(L)1 inhibition. So far,
THIO-101 has demonstrated favorable disease control, progression
free survival, overall response rates, and we remain on track to
achieve our overall survival goals,” said MAIA Chairman and Chief
Executive Officer Vlad Vitoc, M.D.
Under terms of the amended clinical supply agreement, MAIA
continues to sponsor THIO-101 and Regeneron will provide Libtayo®
for the treatment of all patients in the trial including the
additional patients in the THIO 101 expansion. MAIA holds an
exclusive worldwide patent license to develop and commercialize
THIO.
MAIA expects to start enrolling new patients in the expansion of
THIO-101 in the near future.
The company continues to evaluate its regulatory strategy and
believes that there could be an opportunity for an accelerated
approval in the United States based on the ultimate outcome of the
ongoing THIO 101 trial.
About THIO
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class
investigational telomere-targeting agent currently in clinical
development to evaluate its activity in Non-Small Cell Lung Cancer
(NSCLC). Telomeres, along with the enzyme telomerase, play a
fundamental role in the survival of cancer cells and their
resistance to current therapies. The modified nucleotide
6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent
telomeric DNA modification, DNA damage responses, and selective
cancer cell death. THIO-damaged telomeric fragments accumulate in
cytosolic micronuclei and activates both innate (cGAS/STING) and
adaptive (T-cell) immune responses. The sequential treatment with
THIO followed by PD-(L)1 inhibitors resulted in profound and
persistent tumor regression in advanced, in vivo cancer models by
induction of cancer type–specific immune memory. THIO is presently
developed as a second or later line of treatment for NSCLC for
patients that have progressed beyond the standard-of-care regimen
of existing checkpoint inhibitors.
About THIO-101, a Phase 2 Clinical Trial
THIO-101 is a multicenter, open-label, dose finding Phase 2
clinical trial. It is the first trial designed to evaluate THIO’s
anti-tumor activity when followed by PD-(L)1 inhibition. The trial
is testing the hypothesis that low doses of THIO administered prior
to cemiplimab (Libtayo®) will enhance and prolong immune response
in patients with advanced NSCLC who previously did not respond or
developed resistance and progressed after first-line treatment
regimen containing another checkpoint inhibitor. The trial design
has two primary objectives: (1) to evaluate the safety and
tolerability of THIO administered as an anticancer compound and a
priming immune activator (2) to assess the clinical efficacy of
THIO using Overall Response Rate (ORR) as the primary clinical
endpoint. Treatment with THIO followed by cemiplimab (Libtayo®) has
been generally well-tolerated to date in a heavily pre-treated
population. For more information on this Phase II trial, please
visit ClinicalTrials.gov using the identifier NCT05208944.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is THIO, a potential first-in-class cancer
telomere targeting agent in clinical development for the treatment
of NSCLC patients with telomerase-positive cancer cells. For more
information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation,
timing, cost, progress and results of our preclinical and clinical
studies and our research and development programs, (ii) our ability
to advance product candidates into, and successfully complete,
clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and
commercialize our product candidates and to improve the
manufacturing process, (v) the rate and degree of market acceptance
of our product candidates, (vi) the size and growth potential of
the markets for our product candidates and our ability to serve
those markets, and (vii) our expectations regarding our ability to
obtain and maintain intellectual property protection for our
product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and
expectations by our management that, although we believe to be
reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is
expressed in good faith and believed to be reasonable at the time
such forward-looking statement is made. However, these statements
are not guarantees of future events and are subject to risks and
uncertainties and other factors beyond our control that may cause
actual results to differ materially from those expressed in any
forward-looking statement. Any forward-looking statement speaks
only as of the date on which it was made. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. In this release, unless the
context requires otherwise, “MAIA,” “Company,” “we,” “our,” and
“us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241203280964/en/
Investor Relations Contact +1 (872) 270-3518
ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
